Clinic
Puyallup Tribal Health Authority
Puyallup Tribal Health Authority was paid $70.41M by Medicaid between Jan 2018 and Dec 2024, across 124 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 93% of everything it billed.
33Billing provider infoPUYALLUP TRIBAL HEALTH AUTHORITY
TACOMA, WA 98404
TACOMA, WA 98404
33aNPI1063455665assigned 06/13/2006
33bProvider typePodiatric Clinic/Center
28Total paid$70.41M
24GClaims322,976
24DCodes billed124
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Podiatric Clinic/Center providers in Washington
Rank by total paid#1 of 8
Median peer was paid$16K
This provider vs. median4,275×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,904 | $6.87M | |
| 2019 | 40,457 | $6.97M | |
| 2020 | 23,539 | $5.03M | |
| 2021 | 59,013 | $11.84M | |
| 2022 | 55,681 | $13.79M | |
| 2023 | 54,163 | $12.72M | |
| 2024incomplete | 46,219 | $13.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 93% | 141,706 | 123,593 | $65.43M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.2% | 35,174 | 30,926 | $1.55M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 10,772 | 9,642 | $541K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,432 | 7,077 | $359K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,499 | 7,131 | $152K |
| D1206 | Topical application of fluoride varnish | <1% | 8,356 | 8,253 | $146K |
| D0120 | Dental checkup, returning patientPeriodic oral evaluation - established patient | <1% | 5,227 | 5,203 | $145K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,564 | 1,463 | $122K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,523 | 1,394 | $119K |
| D0140 | Limited oral evaluation - problem focused | <1% | 4,731 | 4,606 | $119K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,183 | 1,931 | $113K |
| D1120 | Dental cleaning, childProphylaxis - child | <1% | 4,680 | 4,667 | $108K |
112 more codes
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,622 | $86K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,170 | $85K |
| D1351 | Sealant - per tooth | <1% | 6,471 | $85K |
| D8080 | Comprehensive orthodontic treatment of the adolescent dentition | <1% | 234 | $83K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 9,012 | $82K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 2,095 | $81K |
| D1110 | Prophylaxis - adult | <1% | 1,700 | $73K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 946 | $65K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,941 | $63K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 752 | $62K |
| 99442 | <1% | 1,502 | $59K | |
| 99441 | <1% | 2,213 | $57K | |
| D0330 | Panoramic radiographic image | <1% | 1,421 | $44K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 532 | $41K |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 1,704 | $39K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 648 | $35K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 13,908 | $33K |
| D0274 | Bitewings - four radiographic images | <1% | 2,643 | $32K |
| D0272 | Bitewings - two radiographic images | <1% | 3,050 | $30K |
| 99443 | <1% | 630 | $30K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,056 | $26K |
| 90686 | <1% | 2,539 | $24K | |
| D0240 | <1% | 1,792 | $22K | |
| 0012A | <1% | 834 | $20K | |
| D0191 | <1% | 1,565 | $16K | |
| 0001A | <1% | 402 | $15K | |
| 90670 | <1% | 1,064 | $12K | |
| 0002A | <1% | 308 | $12K | |
| 0011A | <1% | 930 | $12K | |
| 0064A | <1% | 381 | $11K | |
| D1999 | <1% | 790 | $11K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 242 | $10K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 183 | $10K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 823 | $9K |
| 80053 | Comprehensive metabolic panel | <1% | 1,293 | $9K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 303 | $9K |
| 82610 | <1% | 734 | $9K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,615 | $9K |
| 0071A | <1% | 229 | $9K | |
| 0072A | <1% | 139 | $5K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 131 | $5K |
| 90651 | <1% | 467 | $5K | |
| 98926 | <1% | 200 | $4K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 322 | $4K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 253 | $4K |
| D0270 | <1% | 667 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 536 | $3K |
| D1354 | <1% | 958 | $3K | |
| 92551 | <1% | 431 | $3K | |
| D8670 | Periodic orthodontic treatment visit | <1% | 88 | $2K |
| 91322 | <1% | 27 | $2K | |
| 82570 | <1% | 500 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 255 | $2K |
| 90677 | <1% | 104 | $2K | |
| 90633 | <1% | 280 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 41 | $2K |
| 90715 | <1% | 199 | $2K | |
| D0160 | <1% | 48 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 128 | $2K |
| 90688 | <1% | 177 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 112 | $1K |
| 90656 | <1% | 184 | $1K | |
| 90734 | <1% | 159 | $1K | |
| 99001 | <1% | 67 | $1K | |
| 80061 | Lipid panel | <1% | 132 | $1K |
| 90710 | <1% | 100 | $1K | |
| 90696 | <1% | 95 | $1K | |
| 90685 | <1% | 132 | $1K | |
| 90619 | <1% | 145 | $1K | |
| 96127 | <1% | 118 | $1K | |
| 82607 | <1% | 76 | $987.37 | |
| D0190 | <1% | 92 | $907.80 | |
| 83721 | <1% | 133 | $878.61 | |
| 90647 | <1% | 117 | $864.04 | |
| 81001 | <1% | 302 | $763.60 | |
| 90480 | <1% | 28 | $720.00 | |
| 81025 | <1% | 88 | $683.66 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 59 | $582.28 |
| 90648 | <1% | 91 | $577.18 | |
| 90680 | <1% | 88 | $574.23 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 17 | $574.05 |
| 98927 | <1% | 15 | $506.70 | |
| 98925 | <1% | 31 | $495.16 | |
| 90698 | <1% | 71 | $472.36 | |
| 0134A | <1% | 16 | $441.63 | |
| 90672 | <1% | 54 | $434.46 | |
| 99177 | <1% | 138 | $369.62 | |
| 90723 | <1% | 57 | $352.20 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $351.23 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $351.23 |
| 84439 | <1% | 43 | $312.21 | |
| 98966 | <1% | 14 | $253.12 | |
| 84146 | <1% | 15 | $231.36 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 15 | $200.20 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 87 | $195.64 |
| 90707 | <1% | 16 | $193.28 | |
| 90716 | <1% | 13 | $167.63 | |
| 87210 | <1% | 39 | $159.67 | |
| D9630 | <1% | 25 | $140.00 | |
| 90681 | <1% | 16 | $83.44 | |
| 85027 | <1% | 13 | $81.64 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 17 | $77.60 |
| 91301 | 0% | 1,735 | $0.00 | |
| 91307 | 0% | 491 | $0.00 | |
| 91306 | 0% | 377 | $0.00 | |
| 91305 | 0% | 89 | $0.00 | |
| D1353 | 0% | 63 | $0.00 | |
| D9992 | 0% | 12 | $0.00 | |
| D4355 | 0% | 14 | $0.00 | |
| 91300 | 0% | 1,034 | $0.00 | |
| D0350 | 0% | 16 | $0.00 | |
| 91313 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENRY, CHRIS (EXECUTIVE DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Puyallup Tribal Health Authority | Tacoma, WA | $19.52M |
| Puyallup Tribal Health Authority | Tacoma, WA | $8.92M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.